Clinical Trials Logo

Clinical Trial Summary

Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.


Clinical Trial Description

Study population included all subjects in study area who signed a written Informed Consent Form diagnosed with Malaria- STS co-infection. Those excluded were treated with PZQ prior 6 weeks, have drug intolerance or pregnant. At Inclusion, Basic Demographic data was recorded and urine samples analysed. During the follow up visits, urine samples were collected on D28 and D42 (6 weeks post treatment). Post treatment assessment was done on urine samples collected on at least two consecutive days and at the end of follow up, all subjects were treated with a single dose pf PZQ (40 mg/kg) as recommended by WHO. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04264130
Study type Interventional
Source Centre de Recherche Médicale de Lambaréné
Contact
Status Completed
Phase Phase 2
Start date July 31, 2018
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03133832 - The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium Phase 3
Completed NCT00138450 - Urinary Schistosomiasis Infection